Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

 SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Toronto Stock Exchange
03/23/2017 03/24/2017 03/27/2017 03/28/2017 03/29/2017 Date
4.07 4.08 4.1 4.1 4.07 Last
300 7840 2100 2700 23900 Volume
+1.50% +0.25% +0.49% 0.00% -0.73% Change
Financials ( CAD)
Sales 2017 42,5 M
EBIT 2017 -14,4 M
Net income 2017 -24,3 M
Debt 2017 -
Yield 2017 -
Sales 2018 54,4 M
EBIT 2018 -19,2 M
Net income 2018 -17,6 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 3,05x
Capi. / Sales2018 2,38x
Capitalization 130 M
More Financials
Company
Cardiome Pharma Corp. is a pharmaceutical company engages in provision of development and commercialization of medical products.It focuses on cardiovascular therapies that will improve the quality of life and health of patients suffering from heart disease.It offers the Brinavess and Aggrastat... 
Sector
Pharmaceuticals
Calendar
05/15Earnings Release
More about the company
Surperformance© ratings of Cardiome Pharma Corp
Trading Rating : Investor Rating :
More Ratings
Latest news on CARDIOME PHARMA CORP
03/23 CARDIOME PHARMA : Reports Fourth Quarter And Full Year 2016 Financial Results
03/17 CARDIOME PHARMA : Receives notice of compliance from health canada for its brina..
03/16 CARDIOME PHARMA CORP : Research Reports Initiated on Healthcare Stocks Cardiome ..
03/14 CARDIOME PHARMA : IIROC Trade Resumption - COM
03/14 IIROC Trade Resumption - Cardiome Pharma Corp.
03/14 CARDIOME PHARMA : Receives Notice of Compliance from Health Canada for its BRINA..
03/14 CARDIOME PHARMA : IIROC Trading Halt - COM
03/14 IIROC Trade Halt - Cardiome Pharma Corp.
03/07 CARDIOME PHARMA : Reports Fourth Quarter and Full Year 2016 Financial Results
03/03 CARDIOME PHARMA : Announces Commercial Launch of Xydalba(TM) (dalbavancin) in Fr..
More news
Sector news : Biopharmaceuticals
03/30 China's Creat makes 1.2 billion euro bid for German blood plasma firm
03/30DJOXFORD BIOMEDICA : Hails U.S. Regulatory Boost for Leukemia Treatment
03/29 FDA, Mylan silence on generic Advair may be good news for GSK
03/29 British business navigates rocky path to Brexit
03/29 ConvaTec's majority investors raise $1.2 billion via stake sale
More sector news : Biopharmaceuticals
News from SeekingAlpha
03/14 Cardiome cleared to commercialize Brinavess in Canada; shares ahead 2%
03/07 Cardiome Pharma's (CRME) CEO Bill Hunter on Q4 2016 Results - Earnings Call T..
03/07 Cardiome Pharma misses by $0.06, beats on revenue
03/03 Cardiome launches antibiotic XYDALBA in France; shares ahead 3%
2016 Recent analyst action
Advertisement
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,3  CAD
Spread / Average Target 178%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Jennifer Archibald Chief Financial Officer
Richard M. Glickman Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP2.78%97
BIOGEN INC2.75%57 990
CSL LIMITED22.50%43 197
ALEXION PHARMACEUTICAL..-1.33%27 115
BIOMARIN PHARMACEUTICA..8.14%15 485
GRIFOLS SA19.78%15 139
More Results